Cantor Fitzgerald Predicts CLDX FY2026 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Celldex Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings per share of ($4.68) for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%.

A number of other research firms also recently weighed in on CLDX. The Goldman Sachs Group decreased their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group started coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a “buy” rating and a $64.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Morgan Stanley lowered their price target on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. Finally, UBS Group cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.90.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $20.71 on Tuesday. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $47.00. The firm has a market cap of $1.37 billion, a P/E ratio of -8.06 and a beta of 1.33. The firm’s 50-day simple moving average is $19.05 and its 200-day simple moving average is $21.90.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Celldex Therapeutics by 0.4% in the first quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company’s stock worth $70,757,000 after purchasing an additional 16,440 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after acquiring an additional 676,771 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock worth $63,579,000 after acquiring an additional 847,264 shares during the period. Deep Track Capital LP bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at $38,919,000. Finally, Rock Springs Capital Management LP raised its position in shares of Celldex Therapeutics by 10.7% during the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company’s stock valued at $30,885,000 after acquiring an additional 118,404 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.